Hologic's International Momentum Takes Shape: Will Execution Pay Off?
While many of Hologic's product successes began in the United States, it has now built the capabilities to scale internationally on a consistent basis. In its Surgical division, the company continues to invest organically, especially in the International business, where it has delivered more than 20% growth for several years. The momentum is supported by increased reimbursement and the promotion of guidelines for its portfolio of product offerings. In the fiscal second quarter of 2025, the International Surgical business rose 16.2% year over year.
MyoSure is seeing even faster gains abroad, fueled by vastly untapped markets and higher demand for minimally invasive options to treat uterine polyps and fibroids. Newly acquired Gynesonics gave a boost, having already generated a healthy mix of international sales before joining Hologic. Now with the support of Hologic's large Gyn sales force, Gynesonics' sales are expected to grow at a strong double-digit rate. NovaSure is also seeing higher sales volume in Europe despite posting domestic declines.
That said, global exposure brings added operational challenges. The company's second-quarter international sales were hurt by the ongoing physician strike in South Korea, reduced hospital spending in China and lower HIV testing sales in Africa due to USAID funding cuts. In China, Hologic's cytology business is now weighed down by tariff implications, anti-American sentiment and intensifying local competition.
International Performance of Hologic's Top Rivals
Becton, Dickinson and Company BDX, or BD, derives a significant portion of its revenues from overseas, with products being distributed either directly or through independent distribution channels and sales representatives. In the second quarter of 2025, BD's international revenues increased 1.2%, driven by gains in the Medical segment's Pharmaceutical Systems unit and the acquired Advanced Patient Monitoring unit's sales. Based on tariffs in effect as of April 30, 2025, BD anticipates a $90 million hit to fiscal year 2025 operating expenses.
Abbott ABT, too, maintains a strong global footprint, with sales outside the United States accounting for approximately 61% of its 2024 net sales. In the second quarter of 2025, international sales increased 6.6% year over year. Abbott remains the global leader in adult nutrition, supported by continued demand for its Ensure and Glucerna brands. ABT's Electrophysiology division also drove strong performance across 15 key markets — including India, China, and other markets across Asia, Latin America and the Middle East — representing some of the most attractive growth areas for branded generic medicines.
HOLX Stock Performance, Valuation and Estimates
Year to date, Hologic shares have declined 8.5% compared with the industry's 10.2% fall.
Image Source: Zacks Investment Research
Hologic is trading at a forward five-year price-to-earnings of 14.84X, lower than the industry average of 28.28X. The stock carries a Value Score of B at present.
Image Source: Zacks Investment Research
Consensus estimates for Hologic's fiscal 2025 EPS are showing a downward trend for the past 90 days.
Image Source: Zacks Investment Research
HOLX stock currently carries a Zacks Rank #4 (Sell).
You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.5% per year. So be sure to give these hand picked 7 your immediate attention.
See them now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Becton, Dickinson and Company (BDX): Free Stock Analysis Report
Hologic, Inc. (HOLX): Free Stock Analysis Report
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
3 hours ago
- Globe and Mail
FLYWIRE SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Flywire Corporation
Kahn Swick & Foti, LLC ('KSF') and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 23, 2025 to file lead plaintiff applications in a securities class action lawsuit against Flywire Corporation ('Flywire' or the 'Company') (NasdaqGS: FLYW), if they purchased the Company's securities between February 28, 2024 and February 25, 2025, inclusive (the 'Class Period'). This action is pending in the United States District Court for the Eastern District of New York. What You May Do If you purchased securities of Flywire and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ( or visit to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by September 23, 2025. About the Lawsuit Flywire and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws. On February 25, 2025, the Company announced its Q4 and FY 2024 financial results, disclosing a loss per share of $0.12 for Q4 2024, missing consensus estimates by $0.12, and revenue of $117.6 million, missing consensus estimates by $1.25 million, which it attributed to 'a complex macro environment with significant headwinds,' and that the Company would 'undertake an operational and business portfolio review' and certain 'efficiency measures' including 'a restructuring, which impacts approximately 10% of our workforce.' The case is Hickman v. Flywire Corporation, et al., No. 25-cv-04110. About Kahn Swick & Foti, LLC KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, New Jersey, and a representative office in Luxembourg. To learn more about KSF, you may visit
Globe and Mail
4 hours ago
- Globe and Mail
CEA Industries and 10X Capital, with the support of YZi Labs, announce $500 Million Private Placement to Establish Largest Publicly-Listed $BNB Treasury Company in the World (NASDAQ:VAPE)
Upsized PIPE offering with potential to deliver up to $1.25 billion of gross proceeds Offering consists of a common equity PIPE delivering $500M in gross proceeds ($400M in cash and $100M in Crypto), plus up to $750M in cash which may be received from exercised warrants to be issued in the private placement (assuming 100% of warrants are exercised). The proceeds of the offering by CEA Industries Inc. (Nasdaq:VAPE) will be used to establish the largest publicly listed BNB Chain digital asset treasury strategy in the world. $BNB is the fourth largest cryptocurrency in the world, with $100B+ market cap, and provides the treasury with opportunities to generate income and rewards on the BNB Chain and Binance ecosystem, the world's #1 digital assets infrastructure by volume, with over 280 million users in over 180 countries. The BNB treasury strategy will be led by incoming CEO David Namdar (Co-founder of Galaxy Digital and Senior Partner at 10X Capital), incoming CIO Russell Read (former CIO of CalPERS and CIO of 10X Capital) and Saad Naja (former director at Kraken and one of the executive board of directors of global retail brokerage firm Exinity). 10X Capital, who also served as financial advisor to Nakamoto, will serve as the asset manager of the BNB treasury strategy, with the support of YZiLabs. Over 140 subscribers, led by institutional and crypto-native investors including YZi Labs, Pantera Capital, Arche Capital, GSR, Borderless, Arrington Capital, Hypersphere Capital, Kenetic, dao5, Protocol Ventures, Reciprocal Ventures, G-20 Group, Three Point Capital, Propel Horizon, Exinity, Winone, Nano Labs, and several other prominent investors including Olaf Carlson Wee, Rajeev Misra's family office and the founders of BitFury, participated in the offering. The transaction is expected to close on or around July 31, 2025. Louisville, CO, July 28, 2025 (GLOBE NEWSWIRE) -- CEA Industries Inc. (Nasdaq:VAPE) (the 'Company') and 10X Capital, with support from YZi Labs, today announced the pricing of an oversubscribed and upsized above-the-market PIPE financing, positioning the Company to become the largest publicly traded BNB Treasury Company in the United States. This milestone marks a significant evolution from 10X Capital & YZi Labs' initial announcement in early July, officially bringing $BNB—a top-four digital asset token with over $100 Billion in market capitalization—into U.S. public markets at institutional scale through a dedicated treasury vehicle. Following the closing, the Company intends to begin deploying funds to acquire BNB, creating a gateway for institutional and retail investors to participate in the BNB Chain ecosystem, which powers millions of users and decentralized applications worldwide. Following closing, the Company's management team is expected to include significant institutional expertise, including from incoming CEO David Namdar (Co-Founder, Galaxy Digital and Senior Partner, 10X Capital), incoming CIO Russell Read (CIO, 10X Capital and former CIO of CalPERS, Deputy CIO of Deutsche Bank Asset Management) and Saad Naja (former director at Kraken and one of the executive board of directors of global retail brokerage firm Exinity). Reflecting significant demand for BNB exposure, the PIPE included over 140 subscribers from around the world, led by institutional and crypto-native investors including YZi Labs, Pantera Capital, Arche Capital, GSR, Borderless, Arrington Capital, Hypersphere Capital, Kenetic, dao5, Protocol Ventures, Reciprocal Ventures, G-20 Group, Three Point Capital, Propel Horizon, Exinity, Winone, Nano Labs, and several other prominent investors including Olaf Carlson Wee, Rajeev Misra's family office and the founders of BitFury. The Company expects to be positioned among the largest publicly traded vehicles offering exposure to a single Layer-1 blockchain following closing of the PIPE. 'BNB Chain is one of the most widely used blockchain ecosystems globally, yet institutional access has been limited until now. By creating a U.S.-listed treasury vehicle, we are opening the door for traditional investors to participate in a transparent way. This is a significant step in bridging digital assets and mainstream capital markets," said incoming CEO David Namdar. 'Institutional-grade exposure to BNB is attractive because it is driven by fundamentals rather than speculation. BNB powers one of the largest ecosystems in blockchain — with real network utility across DeFi, payments and enterprise applications. By creating a treasury vehicle, we're allowing institutions to participate in that growth story in a way that aligns with their need for transparency and long-term value, rather than short-term trading opportunities,' said incoming CIO Russell Read. BNB Treasury Strategy & Institutional Roadmap Following closing, the Company expects to: Build an initial BNB position with plans to significantly scale holdings over the next 12–24 months via a best-in-class capital markets program incorporating ATM sales and other proven strategies. Evaluate staking, lending and other opportunities throughout the Binance ecosystem to generate revenue from the BNB Treasury, while maintaining a conservative risk profile. 'When YZi Labs first announced our support earlier this month, it was because we recognized the institutional potential of a publicly listed BNB treasury vehicle.' said Ella Zhang, Head of YZi Labs. 'With the successful announcement of this PIPE, that conviction is now validated. We're proud to see this vision come to life — expanding BNB's utility and institutional access in a meaningful and sustainable way.' 'Treasury companies have proven to be the cleanest, most transparent gateway for institutions to access digital assets. With BNB powering hundreds of millions of users globally, this marks the right time for a well-capitalized BNB treasury company to enter the U.S. market,' said Hans Thomas, Founder and CEO of 10X Capital. The PIPE highlights a growing trend where publicly traded treasury companies are emerging as a new asset class for U.S. investors, building on the success of Bitcoin-focused vehicles such as MicroStrategy and recent treasury players such as Sharplink Gaming, Bitmine Immersion, and DeFi Development Corp. Importantly, ongoing crypto regulatory bills and signals from U.S. lawmakers are injecting confidence and laying the groundwork for greater market participation, providing institutional investors with increased regulatory certainty. Unlike those Bitcoin-focused and other treasury plays, this treasury vehicle is exclusively dedicated to the BNB Chain, offering exposure to a fast-growing Layer-1 network with strong DeFi, NFT and Web3 adoption. Trading & Next Steps The Company's common stock will continue to trade on the Nasdaq Capital Market under the ticker 'VAPE', with the updated treasury strategy effective immediately following the closing, which is expected to take place on or about July 31, 2025. The Company will emphasize transparency and verification of holdings, strong engagement with the BNB ecosystem and community. Additional updates on BNB acquisitions, treasury growth and governance measures are expected in the coming weeks. Advisors Cantor Fitzgerald & Co. served as lead financial advisor to 10X Capital and sole placement agent to the Company. Cohen & Company Capital Markets, a division of Cohen & Company Securities, LLC, and Clear Street LLC served as financial advisors to 10X Capital. Winston & Strawn LLP served as counsel to 10X Capital. DLA Piper LLP (US) served as counsel to Cantor Fitzgerald & Co. Disclaimer: The information provided in this press release is intended for informational purposes only and does not constitute investment advice, endorsement, analysis, or recommendations with respect to any financial instruments, investments, or issuers. Investment in cryptocurrency and DeFi projects involves substantial risk, including the risk of complete loss. This press release does not take into account the investment objectives, financial situation, or specific needs of any particular person and each individual is urged to consult their legal and financial advisors before making any investment decisions. Cautionary Note Regarding Forward-Looking Statements This press release contains statements that constitute 'forward-looking statements' within the meaning of the U.S. federal securities laws. Forward-looking statements are statements other than historical facts and include, without limitation, statements regarding the potential for and amount of additional cash proceeds from warrant exercises, the anticipated closing date of the PIPE, use of proceeds from the announced PIPE, future announcements and priorities, expectations regarding management, market position, business strategies, future financial and operating performance, and other projections or statements of plans and objectives. These forward-looking statements are based on current expectations, estimates, assumptions, and projections, and involve known and unknown risks, uncertainties, and other factors—many of which are beyond the Company's control—that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such statements. Important factors that may affect actual results include, among others, the Company's ability to execute its growth strategy; its ability to raise and deploy capital effectively; developments in technology and the competitive landscape; the market performance of BNB; and other risks and uncertainties described under 'Risk Factors' in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission (the 'SEC') on March 27, 2025, and in other subsequent filings with the SEC. These filings are available at The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. -ends- About 10X Capital 10X Capital is a next-generation investment firm focused on digital transformation, including digital assets and digital infrastructure. Founded by pioneering digital currency and fintech entrepreneur Hans Thomas (founding team, InternetCash), 10X Capital brings institutional capital to exceptional opportunities worldwide. With capabilities in asset management, treasury management, and capital markets, the firm takes a holistic approach to building and managing Digital Assets Treasury companies around the world, in partnership with top foundations & entrepreneurs. About YZi Labs YZi Labs manages over $10 billion in assets globally. Its investment philosophy emphasizes impact first—YZi Labs believes that meaningful returns will naturally follow. YZi Labs invests in ventures at every stage, prioritizing those with solid fundamentals in Web3, AI, and biotech. YZi Labs' portfolio covers over 300 projects from over 25 countries across six continents. More than 65 of YZi Labs' portfolio companies have gone through our incubation programs. For more information, follow YZi Labs on X. About CEA Industries Inc. CEA Industries Inc. (Nasdaq:VAPE) is a growth-oriented company that has focused on building category-leading businesses in regulated consumer markets, including the high-growth, Canadian nicotine vape industry. CEA Industries targets scalable operators with strong regulatory alignment, defensible market share, and high-margin business models. Following the closing of the PIPE, CEA intends to adopt a BNB Treasury strategy, offering a gateway for institutional and retail investors to participate in the BNB Chain ecosystem, Binance Layer-1 blockchain ecosystem coin.
Globe and Mail
4 hours ago
- Globe and Mail
Cutaneous T-Cell Lymphoma Pipeline Outlook Report 2025: Key 25+ Companies and Breakthrough Therapies Shaping the Future Landscape
DelveInsight's ' Cutaneous T-cell lymphoma Pipeline Insight 2025 ' report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in the Cutaneous T-cell lymphoma pipeline landscape. It covers the Cutaneous T-Cell Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Cutaneous T-Cell Lymphoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Cutaneous T-Cell Lymphoma Treatment Landscape. Click here to read more @ Cutaneous T-Cell Lymphoma Pipeline Outlook Key Takeaways from the Cutaneous T-Cell Lymphoma Pipeline Report In July 2025, Prescient Therapeutics Ltd. announced a phase 2 study to evaluate the efficacy, safety, pharmacokinetics (PK) and pharmadynamics (PD), of PTX-100 monotherapy at 500 or 1000 mg/m2 in patients with relapsed/refractory Cutaneous T-Cell Lymphoma (CTCL). In July 2025, Dren Bio conducted a Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-01 in adult patients with large granular lymphocytic leukemia or cytotoxic lymphomas. In July 2025, Soligenix announced a Phase 3 study is to evaluate the ability of an 18-week course of HyBryte and visible light to induce a Treatment Response in patients with patch/plaque phase CTCL compared to patients receiving placebo and visible study will evaluate the efficacy and safety of HyBryte (0.25% hypericin) gel or placebo gel applied twice weekly for 18 weeks. Treated lesions will be covered with opaque material (such as opaque clothing), followed 21 (±3) hours later by the administration of visible light. DelveInsight's Cutaneous T-Cell Lymphoma pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for Cutaneous T-Cell Lymphoma treatment. The leading Cutaneous T-Cell Lymphoma Companies such as HyBryte, Resminostat, Mundipharma International, Shanghai Pharmaceuticals Holding, Moleculin Biotech, Inc., BeiGene, Mundipharma Research Limited, Jiangsu Simcere Biologics Co., Ltd, Teva Pharmaceuticals USA, Pfizer, Galderma R&D, Merck Sharp & Dohme LLC, Bio-Path Holdings, Inc., Kymera Therapeutics, Inc., Karyopharm Therapeutics Inc and others. Promising Cutaneous T-Cell Lymphoma Pipeline Therapies such as E7777, CD11301 0.03%, Panobinostat, ONTAK (denileukin difitox, DAB389IL-2), Quisinostat, 12 mg, APO866, Enzastaurin, SGX301 (synthetic hypericin), Mogamulizumab, Romidepsin (depsipeptide, FK228), and others. Stay informed about the cutting-edge advancements in Cutaneous T-Cell Lymphoma Treatments. Download for updates and be a part of the revolution in oncology care @ Cutaneous T-Cell Lymphoma Clinical Trials Assessment Cutaneous T-cell lymphoma Emerging Drugs HyBryte™ (synthetic hypericin or SGX301) is a novel, first-in-class, photodynamic therapy utilizing safe, visible light for activation. The active ingredient in HyBryte™ is synthetic hypericin, a potent photosensitizer that is topically applied to skin lesions that is taken up by the malignant T-cells, and then activated by visible light approximately 24 hours later. The use of visible light in the red-yellow spectrum has the advantage of penetrating more deeply into the skin (much more so than ultraviolet light) and therefore potentially treating deeper skin disease and thicker plaques and lesions. Synthetic hypericin sodium, the active ingredient in HyBryte™, has Orphan Drug designation in the United States for the treatment of T-cell lymphoma and CTCL and in Europe for CTCL. HyBryte™ has received Fast Track designation for the treatment of cutaneous t-cell lymphoma in the United States. AFM13: Affimed GmbH AFM-13 is under development for the treatment of refractory and relapsed Hodgkin lymphoma, CD30+ lymphoma such as transformed mycosis fungoides, peripheral and cutaneous T-cell lymphoma, large B-cell lymphoma, B-cell non-Hodgkin lymphoma, Hodgkin lymphoma combination with check point inhibitors and Hodgkin lymphoma combination with lenalidomide. The drug candidate is administered intravenously. AFM-13 is a bi-specific, tetravalent human antibody, it acts by targeting CD30/CD16A. The drug is currently in Phase II stage of its development for the treatment of Cutaneous T Cell Lymphoma. ASTX660: Otsuka Pharmaceutical Co., Ltd ASTX660 (Tolinapant) is a novel, orally administered, non-peptidomimetic antagonist of the cellular and X-linked inhibitors of apoptosis proteins (cIAP1/2 and XIAP). Inhibitors of apoptosis proteins (IAPs) are frequently overexpressed in tumor cells and contribute to tumor cell survival and chemo-resistance. By inhibiting IAPs, tolinapant promotes cell death. Tolinapant also acts via a newly described immunomodulatory mechanism, which works to enhance an anti-tumor immune response in T-cell lymphomas. The drug is in Phase I/II for the treatment of CTCL. WUCART007: Wugen WU-CART-007 is an allogeneic, off-the-shelf, fratricide-resistant CD7-targeted CAR-T cell therapy engineered to overcome the technological challenges of harnessing CAR-T cells to treat CD7+ hematological malignancies. Wugen is deploying CRISPR/Cas9 gene editing technology to delete CD7 and the T-cell receptor alpha constant (TRAC), preventing CAR-T cell fratricide and mitigating the risk of graft-versus-host-disease (GvHD). WU-CART-007 is manufactured using healthy donor-derived T-cells to eliminate the risk of malignant cell contamination historically observed in the autologous CAR-T setting. Currently, the drug is in Phase I stage of its clinical trial for the treatment of CTCL. The Cutaneous T-Cell Lymphoma pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Cutaneous T-Cell Lymphoma with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cutaneous T-Cell Lymphoma Treatment. Cutaneous T-Cell Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Cutaneous T-Cell Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cutaneous T-Cell Lymphoma market. Get a detailed analysis of the latest innovations in the Cutaneous T-Cell Lymphoma pipeline. Explore DelveInsight's expert-driven report today! @ Cutaneous T-Cell Lymphoma Unmet Needs Cutaneous T-Cell Lymphoma Companies HyBryte, Resminostat, Mundipharma International, Shanghai Pharmaceuticals Holding, Moleculin Biotech, Inc., BeiGene, Mundipharma Research Limited, Jiangsu Simcere Biologics Co., Ltd, Teva Pharmaceuticals USA, Pfizer, Galderma R&D, Merck Sharp & Dohme LLC, Bio-Path Holdings, Inc., Kymera Therapeutics, Inc., Karyopharm Therapeutics Inc and others. Cutaneous T-cell lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical Cutaneous T-Cell Lymphoma Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Discover the latest advancements in Cutaneous T-Cell Lymphoma Treatment by visiting our website. Stay informed about how we're transforming the future of oncology @ Cutaneous T-Cell Lymphoma Market Drivers and Barriers, and Future Perspectives Scope of the Cutaneous T-Cell Lymphoma Pipeline Report Coverage- Global Cutaneous T-Cell Lymphoma Companies- HyBryte, Resminostat, Mundipharma International, Shanghai Pharmaceuticals Holding, Moleculin Biotech, Inc., BeiGene, Mundipharma Research Limited, Jiangsu Simcere Biologics Co., Ltd, Teva Pharmaceuticals USA, Pfizer, Galderma R&D, Merck Sharp & Dohme LLC, Bio-Path Holdings, Inc., Kymera Therapeutics, Inc., Karyopharm Therapeutics Inc and others. Cutaneous T-Cell Lymphoma Pipeline Therapies- E7777, CD11301 0.03%, Panobinostat, ONTAK (denileukin difitox, DAB389IL-2), Quisinostat, 12 mg, APO866, Enzastaurin, SGX301 (synthetic hypericin), Mogamulizumab, Romidepsin (depsipeptide, FK228), and others. Cutaneous T-Cell Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Cutaneous T-Cell Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III For a detailed overview of our latest research findings and future plans, read the full details of Cutaneous T-Cell Lymphoma Pipeline on our website @ Cutaneous T-Cell Lymphoma Emerging Drugs and Companies Table of Content Introduction Executive Summary Cutaneous T-cell lymphoma: Overview Pipeline Therapeutics Therapeutic Assessment Cutaneous T-cell lymphoma– DelveInsight's Analytical Perspective Late Stage Products (Phase III) Drug Name: Company Name Mid Stage Products (Phase II) AFM13: Affimed GmbH Early Stage Products (Phase I) WUCART007: Wugen Preclinical Stage Products Drug Name: Company Name Inactive Products Cutaneous T-cell lymphoma Key Companies Cutaneous T-cell lymphoma Key Products Cutaneous T-cell lymphoma- Unmet Needs Cutaneous T-cell lymphoma- Market Drivers and Barriers Cutaneous T-cell lymphoma- Future Perspectives and Conclusion Cutaneous T-cell lymphoma Analyst Views Cutaneous T-cell lymphoma Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
